FDA label

What is Cotempla XR-ODT used for?

Cotempla XR-ODT contains methylphenidate. The FDA-approved uses below are quoted from the Indications and Usage section of its DailyMed label.

Source: DailyMed SPL label file dated 2026-10-23. Publisher page

The FDA label says: “COTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.”

Run it in Rivvi

Which 2027 plans near you dropped or restricted Cotempla XR-ODT?

Tier changes and new prior auth, step therapy or quantity limits, plan by plan.

Free to start. Opens Rivvi, the AI workspace for healthcare teams.

Cotempla XR-ODT, tablet, orally disintegrating

Indications and Usage, quoted from the label by Neos Therapeutics Brands, LLC (NDA205489). Cross-references to other label sections are left out.

COTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.

Limitations of Use

The use of COTEMPLA XR-ODT is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.

Source: DailyMed label, set id 33f70f58-c871-42c8-8adb-345caeafefcd, version 16, effective March 2, 2026. NDC 70165-100, one of 3 listings for this product.

Questions

What is Cotempla XR-ODT used for?

The FDA label says: “COTEMPLA XR-ODT is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age.”

What drug class is Cotempla XR-ODT?

FDA lists methylphenidate in the Central Nervous System Stimulant established pharmacologic class.

Does this page cover off-label uses or dosing?

No. This page shows only the Indications and Usage section of the FDA label. Ask a pharmacist or prescriber about dosing.

More on Cotempla XR-ODT

Try it on your own data today.

Free to start. Most teams are using it the same day.